Highlights
- 1
Publications
10 publications
Funding
4 grants
Active
2 grants- KPARIA-IMPACT-006ARIA IMPACT (Aligning Research to Impact Autism Innovative Medicine and Precision Approaches to Clinical Trials) Network GrantSergey Brin Family Foundation · 2026–2027 · via Research Foundation for Mental Hygiene, Inc.
- MPIP50HD109879-04Prospective Genetic Risk Evaluation and Assessment in Autism (subaward)Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2022–2026 · via Columbia University
Completed grants (2)
- Sub-PIRFMH 251486-01An Exploratory, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Arbaclofen in Subjects with 16p11.2 deletion (Subaward)Clinical Research Associates, LLC · 2024–2025 · via Research Foundation for Mental Hygiene, Inc.
- Sub-PIRFMH 223332-01A Randomized Double-Blind, Placebo-Controlled, Parallel Group Multi Center Study Investigating the (subaward)Janssen Research & Development, LLC · 2021–2022 · via Research Foundation for Mental Hygiene, Inc.
Clinical research
5 studies
Active
2 studies- PINCT07091279Randomized Controlled Trial of Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With AutismPHASE2 · New York State Pyschiatric Institute · OPEN TO ACCRUAL (as of 2026)Autism Spectrum Disorder; Challenging Behaviour; Aggression; Severe Disruptive Behaviour Disorders; Self-injury
- PINCT05999240A Target Engagement Study of Pimavanserin for Behavioral Inflexibility With Open Label Trial for Rigid Rigid-compulsive Behavior in Adolescents and Adults With AutismPHASE2 · Research Foundation for Mental Hygiene, Inc. · OPEN TO ACCRUAL (as of 2025)Autism Spectrum Disorder
Completed & closed trials (3)
- PINCT05081245A Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).PHASE2 · MapLight Therapeutics, Inc · IRB STUDY CLOSURE (as of 2026)Autism Spectrum Disorder
- PINCT04271332An Exploratory, Randomized, Double-Blind, Placebo-Controlled and Open-label Extension Study of the Safety, Tolerability, and Efficacy of Arbaclofen in Subjects With 16p11.2 DeletionPHASE2 · Clinical Research Associates, LLC · IRB STUDY CLOSURE (as of 2025)16P11.2 Deletion Syndrome
- PINCT05067582A Randomized, Double-Blind, Chronic Dosing (12-weeks), Two-Period, Placebo-Controlled, Crossover, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Two Doses of L1-79 for the Treatment of the Core Deficits in Social-Communication Interaction in Adolescents and Young Adults With Autism Spectrum DisorderPHASE2 · Yamo Pharmaceuticals · IRB STUDY CLOSURE (as of 2024)Autism Spectrum Disorder; Autism